Rezafungin acetate is under clinical development by Cidara Therapeutics and currently in Phase III for Fungal Infections. According to GlobalData, Phase III drugs for Fungal Infections have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Rezafungin acetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Rezafungin acetate overview

Rezafungin acetate is under development for the treatment and prophylaxis of aspergillosis in COVID-19 patients, pneumocystis pneumonia,Trichophyton mentagrophytes, Trichophyton rubrum, Microsporum gypseum, systemic candida infections including candidemia and related cases of invasive candidiasis. The drug candidate is a long acting echinocandin. It is administered intravaginally, subcutaneously and intravenously as a solution and a gel. The drug candidate was under development for the treatment of vulvovaginal candidiasis.

Cidara Therapeutics overview

Cidara Therapeutics (Cidara) formerly K2 Therapeutics is a biotechnology company. The company discovers, develops and commercializes novel anti-infectives including immunotherapies. Its pipeline products include rezafungin for the treatment of invasive fungal disease and CD388 for treating influenza. Cidara is investigating RSV AVC program for the treatment of respiratory syncytial virus (RSV), HIV AVC for human immunodeficiency viruses (HIV), CoV AVC for pan coronavirus. The company’s proprietary Cloudbreak, an antiviral platform for the fight against life-threatening infectious diseases that provides potent antiviral activity and immune system engagement in a single molecule. Cidara is headquartered in San Diego, California, the US.

For a complete picture of Rezafungin acetate’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.